MX2021002531A - Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. - Google Patents
Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.Info
- Publication number
- MX2021002531A MX2021002531A MX2021002531A MX2021002531A MX2021002531A MX 2021002531 A MX2021002531 A MX 2021002531A MX 2021002531 A MX2021002531 A MX 2021002531A MX 2021002531 A MX2021002531 A MX 2021002531A MX 2021002531 A MX2021002531 A MX 2021002531A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical use
- present application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91148—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
Abstract
La presente solicitud proporciona un anticuerpo anti-CD38, un fragmento de unión al antígeno del mismo y uso farmacéutico. Específicamente, la presente solicitud proporciona un anticuerpo derivado de murino, un anticuerpo quimérico o un anticuerpo humanizado que comprende una región CDR del anticuerpo anti-CD38, una composición farmacéutica que comprende el anticuerpo anti- CD38 o su fragmento de unión al antígeno, y una aplicación del mismo como fármaco. En particular, la presente solicitud proporciona una aplicación de un anticuerpo anti-CD38 humanizado en la preparación de un fármaco para tratar una enfermedad o trastorno positivo para CD38.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811060341 | 2018-09-11 | ||
PCT/CN2019/105119 WO2020052546A1 (zh) | 2018-09-11 | 2019-09-10 | 抗cd38抗体、其抗原结合片段及医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002531A true MX2021002531A (es) | 2021-04-28 |
Family
ID=69777131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002531A MX2021002531A (es) | 2018-09-11 | 2019-09-10 | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220275100A1 (es) |
EP (1) | EP3851456A4 (es) |
JP (1) | JP2021536254A (es) |
KR (1) | KR20210057752A (es) |
CN (1) | CN112513087B (es) |
AU (1) | AU2019338999A1 (es) |
BR (1) | BR112021004130A2 (es) |
CA (1) | CA3111651A1 (es) |
MX (1) | MX2021002531A (es) |
TW (1) | TW202035454A (es) |
WO (1) | WO2020052546A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202325743A (zh) * | 2021-07-14 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合cd38、bcma和cd3的抗原結合分子及其醫藥用途 |
WO2023045859A1 (zh) * | 2021-09-23 | 2023-03-30 | 非同(成都)生物科技有限公司 | Cd38单克隆抗体及其应用 |
CN113912727B (zh) * | 2021-11-16 | 2023-05-02 | 福州迈新生物技术开发有限公司 | 抗cd38蛋白单克隆抗体、细胞系及其制备方法和应用 |
CN114409788B (zh) * | 2022-03-04 | 2022-10-04 | 四川大学华西医院 | 抗cd38的抗体及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
EA037929B1 (ru) * | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
CN106434683B (zh) | 2005-10-12 | 2020-03-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
EP4180058A1 (en) | 2015-04-08 | 2023-05-17 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
IL305540A (en) | 2016-03-04 | 2023-10-01 | Morphosys Ag | Clinical evaluation of protein-M response in multiple myeloma |
JP2021519295A (ja) * | 2018-03-28 | 2021-08-10 | 武田薬品工業株式会社 | 抗cd38抗体の皮下投薬 |
CN109053892B (zh) * | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
-
2019
- 2019-09-10 BR BR112021004130-3A patent/BR112021004130A2/pt not_active Application Discontinuation
- 2019-09-10 KR KR1020217009542A patent/KR20210057752A/ko unknown
- 2019-09-10 US US17/274,082 patent/US20220275100A1/en active Pending
- 2019-09-10 CA CA3111651A patent/CA3111651A1/en active Pending
- 2019-09-10 CN CN201980049843.1A patent/CN112513087B/zh active Active
- 2019-09-10 AU AU2019338999A patent/AU2019338999A1/en not_active Abandoned
- 2019-09-10 JP JP2021512532A patent/JP2021536254A/ja active Pending
- 2019-09-10 WO PCT/CN2019/105119 patent/WO2020052546A1/zh unknown
- 2019-09-10 MX MX2021002531A patent/MX2021002531A/es unknown
- 2019-09-10 EP EP19859106.7A patent/EP3851456A4/en not_active Withdrawn
- 2019-09-11 TW TW108132774A patent/TW202035454A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3111651A1 (en) | 2020-03-19 |
KR20210057752A (ko) | 2021-05-21 |
EP3851456A1 (en) | 2021-07-21 |
EP3851456A4 (en) | 2022-06-08 |
CN112513087A (zh) | 2021-03-16 |
US20220275100A1 (en) | 2022-09-01 |
AU2019338999A1 (en) | 2021-03-18 |
JP2021536254A (ja) | 2021-12-27 |
WO2020052546A1 (zh) | 2020-03-19 |
BR112021004130A2 (pt) | 2021-05-25 |
CN112513087B (zh) | 2023-01-24 |
TW202035454A (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
MX2021002531A (es) | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. | |
MY184154A (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
PH12020552232A1 (en) | IL-11 Antibodies | |
MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
NZ728981A (en) | Anti-ceramide antibodies | |
MX2020002406A (es) | Anticuerpo anti-epha4. | |
MX2021003168A (es) | Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
MX2018007925A (es) | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. | |
MX2019003779A (es) | Uso médico de un conjugado anticuerpo anti-c-met-fármaco citotóxico. | |
MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. |